MD Anderson and Daiichi Sankyo enter research collaboration to accelerate development of acute myeloid leukemia therapies

(University of Texas M. D. Anderson Cancer Center) The University of Texas MD Anderson Cancer Center and Daiichi Sankyo Company, Limited today announced a multi-year collaboration focused on accelerating the development of novel therapies for acute myeloid leukemia (AML).